ELV stock forecast, quote, news & analysis

Key Takeaways

• Elevance Health (ELV) shares closed near $386 in early October 2026, roughly 4.8% below their level from about 30 days earlier, after pulling back from a mid-September peak above $424.
• The company raised its full-year 2026 adjusted earnings guidance to at least $27.00 per share after second-quarter results beat expectations.
• Medicaid remains the central investment theme, with management calling 2026 the "trough" year for segment margins and pointing to improving rate alignment heading into 2027.
• Medicare Advantage and the individual ACA business outperformed in the second quarter, while overall medical membership continues to decline.
• Elevance is scheduled to report third-quarter 2026 results on October 21, 2026.

Current Market Snapshot

Elevance Health, Inc. trades on the New York Stock Exchange under the ticker ELV. After climbing toward the upper end of its 52-week range through mid-September, the stock has eased in recent weeks, settling near $386 as of the most recent completed session. The roughly 4.8% decline over the trailing 30 days reflects a broader rotation away from managed-care names following a period of strength, rather than a single company-specific shock.

Even with the recent pullback, the shares remain higher by roughly 10% year to date and about 19% over the trailing year, supported by a market capitalization of approximately $84 billion. The stock has traded between $274.84 and $436.24 over the past 52 weeks, and the company continues to return capital to shareholders through a $1.72 quarterly dividend.

Elevance Health (ELV) Business Overview and Competitive Position

Elevance Health, formerly known as Anthem, is one of the largest health benefits companies in the United States. It operates Blue Cross and Blue Shield-affiliated plans across multiple states and serves approximately 104 million consumers through medical, pharmacy, behavioral, clinical, home health, and complex care solutions. The company reports through two primary segments: Health Benefits, which includes commercial, Medicare, Medicaid, and federal employee programs, and Carelon, which spans pharmacy services (CarelonRx) and diversified care delivery and services (Carelon Services).

As of June 30, 2026, Elevance served roughly 44.9 million medical members. Its scale, diversified product mix, and growing Carelon platform are key competitive advantages, and investors follow the stock closely as a barometer for medical cost trends and the broader managed-care landscape. Elevance competes alongside peers such as Centene (CNC) and other national insurers across commercial, Medicare, and Medicaid lines of business.

Recent Developments Driving ELV

The most significant catalyst in the period was Elevance's second-quarter earnings report, released in mid-July 2026. The company posted adjusted diluted earnings per share of $7.45, ahead of expectations, on operating revenue of $49.8 billion. Management raised its full-year 2026 adjusted earnings guidance to at least $27.00 per share, up from a prior outlook of at least $26.75, citing favorable benefit expense performance, disciplined cost management, and improving execution across several business lines.

Medicaid dominated the narrative. Elevance maintained its full-year Medicaid operating margin outlook of approximately negative 1.75% while signaling that rate updates received during the quarter were stronger than anticipated. Management reiterated that 2026 is expected to be the trough year for Medicaid margins, with improvement supported by better rate alignment and maturing care management actions. The company also reached a mutual agreement to exit the District of Columbia Medicaid market and indicated it may exit additional markets where sustainable performance is not achievable.

In September 2026, Elevance reaffirmed its full-year outlook, including adjusted earnings of at least $27.00 per share and a benefit expense ratio of approximately 90.2%, plus or minus 50 basis points. On the analyst front, Evercore ISI trimmed its price target to $430 from $440 while maintaining an In Line rating. The broader sell-side consensus remains at Buy, with an average target price near $451, according to recent data.

Trending AI Robots

For investors looking to complement their own analysis with data-driven tools, Tickeron's Trending AI Robots page offers a curated view of automated trading strategies. Tickeron hosts hundreds of AI trading bots that monitor thousands of tickers, but only the top-performing and most relevant bots appear in this featured section. These bots vary widely in strategy, trading timeframe, and performance metrics, so users can evaluate different approaches before deciding whether any align with their own objectives. Exploring the page can provide a useful perspective on how quantitative signals are currently interpreting momentum and sentiment across the market.

2026 Outlook and What Investors Should Watch

Elevance's third-quarter 2026 results, scheduled for October 21, 2026, are the next major catalyst. Investors will focus on whether medical cost trends remain elevated but consistent with pricing assumptions, whether Medicaid rate improvements continue to materialize, and whether the company maintains its full-year adjusted earnings guidance of at least $27.00 per share.

Beyond the quarter, key themes include the trajectory of Medicaid margins into 2027, where management has signaled a return to at least 12% adjusted EPS growth, and the impact of evolving federal policy, including community engagement requirements expected to take effect in several states in January 2027. Medicare Advantage star ratings, 2027 bid positioning, membership attrition, and the growth of Carelon's pharmacy and services platforms will also shape the investment case. As with any insurer, sustained elevation in medical utilization or unfavorable rate actions represent the principal risks to the outlook.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations